Skip to main content
Clinical Trials/NCT01064583
NCT01064583
Completed
Phase 1

Long-term Effect of Dietary Intervention With Flavanol-containing Cocoa on Vascular Function of Diabetic Patients

Heinrich-Heine University, Duesseldorf1 site in 1 country62 target enrollmentOctober 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Peripheral Artery Disease
Sponsor
Heinrich-Heine University, Duesseldorf
Enrollment
62
Locations
1
Primary Endpoint
painfree walking distance
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

To characterize potential vascular long-term effects of flavanols in patients with peripheral artery occlusive disease (PAOD), a placebo-controlled double-blinded randomized control study will be performed in 62 patients randomized in two groups. Patients will twice daily receive either a flavanol-poor cocoa drink or a flavanol-rich cocoa drink over a period of 60 days months.

Detailed Description

62 Type 2 diabetics according to the criteria of the American Diabetes Association suffering from PAOD with a pain free walking distance less than 250m will be enrolled. Patients will twice daily receive either a flavanol-poor cocoa drink (13mg/dl)or a flavanol-rich cocoa drink (596mg/dl) over a period of 60 days. The general condition, the pain free walking distance and the vascular function measured by Doppler Ultrasound will be determined before and two month after cocoa ingestion

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
December 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Heinrich-Heine University, Duesseldorf
Responsible Party
Principal Investigator
Principal Investigator

Klinik für Kardiologie, Pneumologie und Angiologie

Klinik für Kardiologie, Pneumologie und Angiologie

Heinrich-Heine University, Duesseldorf

Eligibility Criteria

Inclusion Criteria

  • peripheral artery disease (Fontaine IIb)
  • diabetes mellitus
  • \> 18 years

Exclusion Criteria

  • acute and terminal renal failure
  • acute infection
  • heart failure (NYHA III-IV)
  • arrhythmias

Outcomes

Primary Outcomes

painfree walking distance

Time Frame: 60 days

Secondary Outcomes

  • endothelial function(60 days)

Study Sites (1)

Loading locations...

Similar Trials